Audentes Therapeutics, Inc. (NASDAQ:BOLD) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $22.25.

A number of brokerages recently weighed in on BOLD. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Evercore ISI began coverage on shares of Audentes Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Wedbush reissued an “ourperform” rating and issued a $20.00 price target on shares of Audentes Therapeutics in a report on Monday, May 15th.

Shares of Audentes Therapeutics (NASDAQ BOLD) opened at 22.63 on Friday. Audentes Therapeutics has a 52 week low of $13.13 and a 52 week high of $23.00. The firm has a 50-day moving average of $20.15 and a 200-day moving average of $17.33. The firm’s market cap is $628.75 million.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, analysts expect that Audentes Therapeutics will post ($3.53) EPS for the current year.

WARNING: “Audentes Therapeutics, Inc. (BOLD) Receives Average Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/08/audentes-therapeutics-inc-bold-receives-average-recommendation-of-hold-from-brokerages.html.

In other news, CEO Matthew R. Patterson sold 2,850 shares of the company’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Louis G. Lange sold 15,000 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $19.78, for a total value of $296,700.00. Following the sale, the director now owns 470,799 shares in the company, valued at $9,312,404.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,850 shares of company stock worth $1,025,220. Company insiders own 47.30% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in BOLD. Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. Nationwide Fund Advisors increased its position in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. Citadel Advisors LLC bought a new stake in shares of Audentes Therapeutics during the first quarter valued at about $184,000. State of Wisconsin Investment Board bought a new stake in shares of Audentes Therapeutics during the second quarter valued at about $210,000. Finally, Rhumbline Advisers bought a new stake in shares of Audentes Therapeutics during the second quarter valued at about $252,000. Hedge funds and other institutional investors own 77.01% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.